Replies to post #543946 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thanks for asking.

The criteria were that they didn’t force trial participants to remain placebo subjects without having the option to try the drug. It is clinically appropriate to treat patients who want treatment.




Another important point to keep in mind is that Liau has specifically stated that FDA mandated crossover for trial participants suffering from GBM. Most recently, she confirmed it during the JAMA interview that Dr. Low published here on iHub—I was so happy to hear her confirm this fact again …Brain surgeons are always so precise and accurate it seems, and we need that kind of clarity amid all the noise.

Skip to timestamp 8:01. Dr. Liau again confirms that the crossover was mandated by the FDA.
https://edhub.ama-assn.org/jn-learning/audio-player/18738384

As NWBO moves toward the next step involving regulatory advisory, it is a good idea to review and fact check this important point once again.

We can hear more clear and precise commentary tonight! Don’t miss this virtual event:

Webinar with Dr. Linda Liau
December 5, 2022
8:30 PM Eastern Time
Topic: DCVax-L (murcidencel)

https://virtualtrials.org/webinar/

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/